Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLGEQ7)

• Drug Name: TAK-861 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Narcolepsy type 1	7A20.0	Phase 2	[1]
Narcolepsy type 2	7A20.1	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DMLGEQ7

Molecule-Related Drug Atlas

Drug(s) Targeting Orexin receptor type 2 (HCRTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Suvorexant	DM0E6S3	Insomnia	7A00-7A0Z	Approved	[4]
MK-3697	DM347TQ	Insomnia	7A00-7A0Z	Phase 2	[5]
MIN-202	DMZFW8V	Major depressive disorder	6A70.3	Phase 2	[6]
TAK-925	DM7N4H9	Narcolepsy	7A20	Phase 1	[7]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 9	DM7I8ZV	N. A.	N. A.	Patented	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Orexin receptor type 2 (HCRTR2)	TT9N02I	OX2R_HUMAN	Agonist	[3]

References

• [1] ClinicalTrials.gov (NCT05687903) A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1). U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05687916) A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2). U.S.National Institutes of Health.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902.
• [8] Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.